BioTuesdays

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in ADHD patients.

Shares of Supernus tumbled $9.20 to finish at $19.93 in heavier than normal turnover on Nov. 6.

Analyst Annabel Samimy writes that the company is holding out for the second Phase 3 trial result before determining the program’s viability. “But for all intents and purposes, we can no longer count on SPN-810’s contribution given a likely extended development pathway, even if the second trial is successful.”

Supernus also posted a third quarter revenue miss as prescriptions for Trokendi and Oxtellar fail to materialize into sales growth. The company also reduced 2019 guidance to $390-million to $395-million from an earlier $400-millon to $410-million.

“In the midst of these dynamics, we expect 2020 growth to slow, though we note R&D expense has attenuated from SPN-810, and the likelihood that Supernus reaches combined peak expectations of more than $500-million before Trokendi exclusivity expires in 2023 has meaningfully decreased,” Ms. Rahimi said. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.